Description: Virios Therapeutics, LLC, a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, LLC in July 2020. Virios Therapeutics, LLC was founded in 2012 and is headquartered in Alpharetta, Georgia.
Home Page: www.virios.com
VIRI Technical Analysis
44 Milton Avenue
Alpharetta,
GA
30009
United States
Phone:
866 620 8655
Officers
| Name | Title |
|---|---|
| Mr. Gregory Duncan | Chairman & CEO |
| Mr. Ralph D. Grosswald M.P.H. | Sr. VP of Operations |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ms. Angela Walsh | CFO, SVP of Fin., Corp. Sec. & Treasurer |
| Ms. Carol Duffy Ph.D. | Chief Scientific Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4988 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-12-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |